Pilot study on developing a decision support tool for guiding re-administration of chemotherapeutic agent after a serious adverse drug reaction

Abstract

BackgroundCurrently, there are no standard guidelines for recommending re-administration of a chemotherapeutic drug to a patient after a serious adverse drug reaction (ADR) incident. The decision on whether to rechallenge the patient is based on the experience of the clinician and is highly subjective. Thus the aim of this study is to develop a decision support tool to assist clinicians in this decision making process.MethodsThe inclusion criteria for patients in this study are: (1) had chemotherapy at National Cancer Centre Singapore between 2004 to 2009, (2) suffered from serious ADRs, and (3) were rechallenged. A total of 46 patients fulfilled the inclusion criteria. A genetic algorithm attribute selection method was used to identify clinical predictors for patients' rechallenge status. A Naïve Bayes model was then developed using 35 patients and externally validated using 11 patients.ResultsEight patient attributes (age, chemotherapeutic drug, albumin level, red blood cell level, platelet level, abnormal white blood cell level, abnormal alkaline phosphatase level and abnormal alanine aminotransferase level) were identified as clinical predictors for rechallenge status of patients. The Naïve Bayes model had an AUC of 0.767 and was found to be useful for assisting clinical decision making after clinicians had identified a group of patients for rechallenge. A platform independent version and an online version of the model is available to facilitate independent validation of the model.ConclusionDue to the limited size of the validation set, a more extensive validation of the model is necessary before it can be adopted for routine clinical use. Once validated, the model can be used to assist clinicians in deciding whether to rechallenge patients by determining if their initial assessment of rechallenge status of patients is accurate.

Concordance Rate between Clinicians and Watson for Oncology among Patients with Advanced Gastric Cancer: Early, Real-World Experience in Korea

“…During validation, WFO yielded a high concordance rate and multidisciplinary team approaches in medical oncology, including for breast [4–6], colon [7, 8], lung [7], and cervical [9] cancer. According to report conducted at MSKCC in the United States (US), the WFO-physician concordance rate was > 90% in 103 patients with nonmetastatic breast cancer [4–6].…”

“…In Thailand, among 211 cases the overall concordance rate was 83%; 89% for colorectal, 91% for lung, 76% for breast, and 78% for gastric cancer. Among 638 patients with breast cancer treated at Manipal Hospitals in Bangalore, India, a 90% concordance rate was observed between the recommendations of a multidisciplinary team (MDT) and WFO [9]. Among patients with cervical cancer [9], treatment recommendations were concordant in 299 (80.8%) of 370 patients: recommended for 277 and for consideration for 22.…”

Artificial Intelligence in Pharmacoepidemiology: A Systematic Review. Part 1—Overview of Knowledge Discovery Techniques in Artificial Intelligence

“…1) Loke et al used a naïve Bayes classifier model to predict the re-occurrence of severe chemotherapyinduced adverse drug reactions in patients with a medical history of this event (Loke et al, 2011). 2) Sudharsan et al used a naïve Bayes classifier model to predict hypoglycemia in patients with type 2 diabetes (Sudharsan et al, 2015).…”